Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: A longitudinal Cohort analysis

Clinical Infectious Diseases

Volumn 57, Issue 5, 2013, Pages 663-670

  Brunet, Laurence ^a   Moodie, Erica E M ^a   Rollet, Kathleen ^b   Cooper, Curtis ^c   Walmsley, Sharon ^d   Potter, Martin ^b   Klein, Marina B ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

cannabis; cohort study; HCV; HIV; liver disease

Indexed keywords

CANNABIS;

ADULT; ARTICLE; CANNABIS SMOKING; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; END STAGE LIVER DISEASE; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT;

CANNABIS; COHORT STUDY; HCV; HIV; LIVER DISEASE;

ADULT; CANADA; COHORT STUDIES; COINFECTION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MARIJUANA SMOKING; MIDDLE AGED;

EID: 84881449276     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit378     Document Type: Article

References (35)

1. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001; 33:562-9.
2. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48:353-67.
3. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: A cohort study. AIDS 2004; 18:2039-45.
4. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to endstage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-7.
5. Adlaf E, Begin P, Sawka E. (Eds). Canadian Addiction Survey (CAS): A national survey of Canadians' use of alcohol and other drugs: Prevalence of use and related harms: Detailed report. Ottawa: Canadian Centre on Substance Abuse, 2005.
6. Furler MD, Einarson TR, Millson M, Walmsley S, Bendayan R. Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDS 2004; 18:215-28.
7. Lim MP, Devi LA, Rozenfeld R. Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis. Cell Death Dis 2011; 2:e170.
8. Mukhopadhyay P, Rajesh M, Horvath B, et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med 2011; 50:1368-81.
9. Avraham Y, Grigoriadis N, Poutahidis T, et al. Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. Br J Pharmacol 2011; 162:1650-8.
10. Parfieniuk A, Flisiak R. Role of cannabinoids in chronic liver diseases. World J Gastroenterol 2008; 14:6109-14.
11. Mallat A, Teixeira-Clerc F, Deveaux V, Manin S, Lotersztajn S. The endocannabinoid system as a key mediator during liver diseases: New insights and therapeutic openings. Br J Pharmacol 2011; 163:1432-40.
12. Huang L, Quinn MA, Frampton GA, Golden LE, DeMorrow S. Recent advances in the understanding of the role of the endocannabinoid system in liver diseases. Dig Liver Dis 2011; 43:188-93.
13. Hezode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42:63-71.
14. Hezode C, Zafrani ES, Roudot-Thoraval F, et al. Daily cannabis use: A novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008; 134:432-9.
15. Ishida JH, Peters MG, Jin C, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 2008; 6:69-75.
16. Whitfield RM, Bechtel LM, Starich GH. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy. Alcohol Clin Exp Res 1997; 21:122-7.
17. Klein MB, Saeed S, Yang H, et al. Cohort profile: The Canadian HIVhepatitis C co-infection cohort study. Int J Epidemiol 2010; 39:1162-9.
18. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-26.
19. Bacchetti P, Tien PC, Seaberg EC, et al. Estimating past hepatitis C infection risk from reported risk factor histories: Implications for imputing age of infection and modeling fibrosis progression. BMC Infect Dis 2007; 7:145.
20. Statistics Canada. Low Income Lines, 2010 to 2011. Income Research Paper Series. Ottawa, 2012.
21. Avraham Y, Amer J, Doron S, et al. The direct pro-fibrotic and indirect immune anti-fibrotic balance of blocking the cannabinoid CB2 receptor. Am J Physiol Gastrointes Liver Physiol 2012; 302:G1364-72.
22. Munoz-Luque J, Ros J, Fernandez-Varo G, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008; 324:475-83.
23. Huang HC, Wang SS, Hsin IF, et al. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats. Hepatology 2012; 56:248-58.
24. Mechoulam R, Parker LA, Gallily R. Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol 2002; 42(11 Suppl):11S-9S.
25. Croxford JL, Yamamura T. Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases?. J Neuroimmunol 2005; 166:3-18.
26. Giannone FA, Baldassarre M, Domenicali M, et al. Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl(4)-induced advanced cirrhosis. Lab Invest: J Techl Methods Pathol 2012; 92:384-95.
27. Toyoda M, Kitaoka A, Machida K, et al. Association between lipid accumulation and the cannabinoid system in Huh7 cells expressing HCV genes. Int J Molecular Med 2011; 27:619-24.
28. van der Poorten D, Shahidi M, Tay E, et al. Hepatitis C virus induces the cannabinoid receptor 1. PLoS One 2010; 5:e12841.
29. Xu X, Liu Y, Huang S, et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 2006; 171: 31-8.
30. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis Crelated fibrosis: An updated meta-analysis. Hepatology 2011; 53: 726-36.
31. Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 2007; 44:463-9.
32. Nunes D, Fleming C, Offner G, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105:1346-53.
33. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449-57.
34. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: A meta-analysis of individual patient data. Gastroenterology 2006; 130:1636-42.
35. Hull MW, Rollet K, Moodie EE, et al. Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients. AIDS 2012; 26:1789-94.